ArticleNutrients2022
Human Milk Oligosaccharides and Lactose Differentially Affect Infant Gut Microbiota and Intestinal Barrier In Vitro.
Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 63 citations in OpenAlex.
- Bifidogenic Effect of 2'-Fucosyllactose (2'-FL) on the Gut Microbiome of Healthy Formula-Fed Infants: A Randomized Clinical Trial.Nutrients · 2025Trial
- Combined HMOs and α-MFGM Ameliorate LPS-Induced Intestinal Mucosal and Systemic Immune Dysfunction via Modulation of Gut Microbiota.Nutrients · 2026Article
- The Response of Mucosal Colonic Microbiota to Probiotic and Dietary Intervention In Vitro.Microorganisms · 2026Article
- The First 1000 Days of PKU: A Narrative Review of Maternal PKU and Early Life Management After Positive Newborn Screening.Nutrients · 2026Review
- Beyond breastfeeding: a One Health Decalogue for nurturing the infant microbiota.Frontiers in nutrition · 2026Review
- Gastrointestinal Journey of Human Milk Oligosaccharides: From Breastfeeding Origins to Functional Roles in Adults.Microorganisms · 2025Review
- Article
- Efficacy of a Ready-to-Feed Starter Liquid Infant Formula Containing 2-Fucosyllactose and Lacto-N-Neotetraose in Chinese Infants: Protocol for a Double Blind, Randomized Controlled Trial.JMIR research protocols · 2025Article
- Early-Life Events and the Prevalence of Gut-Brain Interaction Disorders in Children.Children (Basel, Switzerland) · 2025Article
- HMOs Induce Butyrate Production ofMicroorganisms · 2025Article
- Associations of known and newly identified human milk oligosaccharides with infections in early childhood: the Ulm SPATZ health study.Frontiers in immunology · 2025Article
- 2'-Fucosyllactose as a prebiotic modulates the probiotic responses ofCurrent research in food science · 2025Article
- Recent advances in the science of human milk oligosaccharides.BBA advances · 2025Article
- Are protein substitutes available in Italy for infants with inherited metabolic diseases all the same?Frontiers in nutrition · 2025Article
- Analysis of early childhood intestinal microbial dynamics in a continuous-flow bioreactor.Microbiome · 2024Article
- Development of an infant colon simulatingMicrobiology spectrum · 2024Article
- Linking human milk oligosaccharide metabolism and early life gut microbiota: bifidobacteria and beyond.Microbiology and molecular biology reviews : MMBR · 2024Review
- Review
- Sialyllactose Enhances the Short-Chain Fatty Acid Production and Barrier Function of Gut Epithelial Cells via Nonbifidogenic Modification of the Fecal Microbiome in Human Adults.Microorganisms · 2024Article
- Human milk microbiota and oligosaccharides in colostrum and mature milk: comparison and correlation.Frontiers in nutrition · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe infant gut microbiota establishes during a critical window of opportunity when metabolic and immune functions are highly susceptible to environmental changes, such as diet. Human milk oligosaccharides (HMOs) for instance are suggested to be beneficial for infant health and gut microbiota. Infant formulas supplemented with the HMOs 2'-fucosyllactose (2'-FL) and lacto-N-neotetraose (LNnT) reduce infant morbidity and medication use and promote beneficial bacteria in the infant gut ecosystem. To further improve infant formula and achieve closer proximity to human milk composition, more complex HMO mixtures could be added. However, we currently lack knowledge about their effects on infants' gut ecosystems.
methodWe assessed the effect of lactose, 2'-FL, 2'-FL + LNnT, and a mixture of six HMOs (HMO6: consisting of 2'-FL, LNnT, difucosyllactose, lacto-N-tetraose, 3'- and 6'-sialyllactose) on infant gut microbiota and intestinal barrier integrity using a combination of in vitro models to mimic the microbial ecosystem (baby M-SHIME
resultsAll the tested products had bifidogenic potential and increased SCFA levels; however, only the HMOs' fermented media protected against inflammatory intestinal barrier disruption. 2'-FL/LNnT and HMO6 promoted the highest diversification of OTUs within the
conclusionThese results suggest that increased complexity in HMO mixture composition may benefit the infant gut ecosystem, promoting different bifidobacterial communities and protecting the gut barrier against pro-inflammatory imbalances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.